Daniel Rabinowitz, the Secretary and Chief Legal Officer of Natera, Inc. (NASDAQ:NTRA), recently sold a large portion of his holdings in the company. The sale comes as Natera’s stock trades near a 52-week high of $177, having delivered an impressive 177.73% return over the past year. With a market capitalization of $23.14 billion, the company maintains a GOOD financial health score according to InvestingPro analysis. According to a filing with the Securities and Exchange Commission, Rabinowitz sold 6,223 shares of common stock on January 8, 2025. The shares were traded at a weighted average price of $175.3015, creating a total of approximately $1,090,901.

This transaction was executed as part of a pre-arranged trading plan under Rule 10b5-1, which Rabinowitz adopted on June 14, 2024. After the sale, Rabinowitz retained direct ownership of 199,804 shares of the company.

In other breaking news, Natera Inc (NASDAQ:). expanded its patent infringement lawsuit against NeoGenomics (NASDAQ: ) over the RaDaR assay, a test for molecular residual disease. The company reported a record Q3 revenue of $439.8 million, marking a 64% year-over-year increase, and conducted 137,000 oncology tests, a 54% increase. from last year. Amidst these developments, TD Cowen, Baird, and Jefferies maintained favorable ratings on Natera’s stock and raised their price targets.

Natera also faced a setback in a false advertising lawsuit against Guardian of Health (NASDAQ: ), but plans to ask the court to reverse the decision. In addition, the company amended an agreement with Dr. Rabinowitz, the Executive Chairman, to continue his role under the conditions stipulated in the agreement.

These recent developments provide investors with insights into Natera’s current situation. The company continues to strengthen its position in the genetic testing industry, despite facing legal challenges and a competitive landscape.

This article was created with the support of AI and reviewed by an editor. For more information see our T&C.